Operating cash flow before changes in working capital amounted to -0.6 (1.5) MSEK. Jan-Mar 2024 Jan-Mar 2023 Jan-Dec 2023 Net sales (MSEK ... Rohstoff-Chancen traden In diesem kostenfreien PDF-Report ...

Vaisala Corporation Interim Report May 3 ... totaled EUR 11.4 (Dec 31, 2023: 12.1) million. In January-March 2024, cash flow from operating activities decreased to EUR 17.1 (26.9) million. This was ...

The NFT market has retested some hype this year marked positive gains in sales volume in the Q1,2024, according to a ...

Signed agreements with Clearway Group to commit to invest in 55 MW of wind and 257 MW of solar plus storage projectsEntered into new Resource ...

Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported ...

Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a ...

IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic ...

SharkNinja is off to a strong start in 2024 with outstanding business performance and balanced growth in the first quarter, while driving continued momentum into the second quarter. We are gaining ...

Walt Disney's streaming entertainment unit posted its first profit on Tuesday, two quarters ahead of schedule, and the media company raised its annual earnings per share outlook as it said turnaround ...

SaaS and license revenue increased 11.0% to $150.3 million, compared to $135.4 million for the first quarter of 2023 -- -- First quarter ...

If you had gone to a play last weekend inside a Bloomington warehouse, you might have felt as if you went to the wrong place ...

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors ...